The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
There are questions about vuso-vec’s supporting and confirmatory trials.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
